Middle-East respiratory syndrome coronavirus vaccine - Organic Vaccines

Drug Profile

Middle-East respiratory syndrome coronavirus vaccine - Organic Vaccines

Alternative Names: MERS-CoV vaccine - Organic Vaccines

Latest Information Update: 10 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Organic Vaccines
  • Developer Organic Vaccines
  • Class Monoclonal antibodies; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Middle East respiratory syndrome coronavirus

Most Recent Events

  • 10 Apr 2017 Preclinical development completed in France before April 2014 (Parenteral)
  • 10 Apr 2017 Organic Vaccine's Middle-East respiratory syndrome coronavirus vaccine is available on Compassionate use basis for the treatment/prevention of Middle East respiratory syndrome coronavirus in Saudi Arabia (Parenteral) before April 2017 (Organic Vaccines pipeline, April 2017)
  • 01 Jul 2014 Preclinical trials in Middle East respiratory syndrome coronavirus in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top